Parekoksib

Parekoksib is a nonsteroidal anti-inflammatory drug (NSAID) primarily used for its analgesic (pain-relieving), antipyretic (fever-reducing), and anti-inflammatory properties. It belongs to the class of selective cyclooxygenase-2 (COX-2) inhibitors, which means it targets the COX-2 enzyme more selectively than traditional NSAIDs, reducing the risk of gastrointestinal side effects such as ulcers and bleeding. Parekoksib is typically administered intravenously and is often used in postoperative pain management, particularly following major surgeries like orthopedic procedures or abdominal surgeries.

The drug is metabolized into valdecoxib, another COX-2 inhibitor, which extends its duration of action. Parekoksib was developed as a prodrug, meaning it is converted into its active form once inside the body. Due to its selective mechanism, it is generally considered safer for patients with a history of peptic ulcers or those taking anticoagulants compared to nonselective NSAIDs like ibuprofen or aspirin.

Clinical studies have demonstrated its efficacy in reducing postoperative pain and inflammation while maintaining a favorable safety profile. However, like all COX-2 inhibitors, parekoksib carries risks such as cardiovascular events, particularly with prolonged use or in high doses. It is not recommended for patients with known hypersensitivity to NSAIDs or those with severe renal impairment.

Parekoksib was approved for medical use in several countries, including the European Union and parts of Asia, but its use has declined in some regions due to regulatory restrictions and the availability of alternative pain management options. It is generally prescribed under medical supervision, with dosage adjusted based on individual patient needs and underlying conditions.